H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Autolus Therapeutics Plc (AUTL) today and set a price target of $45. The company’s shares opened today at $31.01.
Chattopadhyay commented:
“We envision upside to our target if the upcoming data reflect the anticipated advantages of Autolus’ CAR T assets. Our $45 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF model. Our DCF is based on: beta of 1.46, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027.”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.0% and a 48.3% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Autolus Therapeutics Plc with a $45 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $53.24 and a one-year low of $19.17. Currently, Autolus Therapeutics Plc has an average volume of 59.89K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.